8-K: Shuttle Pharmaceuticals Appoints Christopher Cooper as Interim Co-CEO to Bolster Business Capabilities

Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO to enhance capital markets and business capabilities, while Dr. Anatoly Dritschilo continues to oversee scientific and clinical trial activities.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. has appointed Christopher Cooper as interim Co-CEO, effective March 11, 2025.
• Mr. Cooper will focus on enhancing the company's capital markets and business capabilities.
• Dr. Anatoly Dritschilo will remain as Co-CEO, overseeing scientific and clinical trial activities.
• Mr. Cooper's consulting agreement with Number 2 Capital Corp. stipulates a monthly fee of $20,000 for a six-month term.
• The agreement can be terminated by either party with 30 days' notice or immediately for cause.
• Mr. Cooper will work approximately 40 hours per week and is subject to confidentiality and non-disclosure provisions.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the appointment of a new Co-CEO to strengthen business capabilities. However, the potential risks associated with the consulting agreement and the company's reliance on Cooper's expertise temper the overall sentiment.

Positives

• The appointment of Christopher Cooper is expected to enhance the company's capital markets and business capabilities.
• The Co-CEO structure allows Dr. Dritschilo to focus on scientific and clinical trial activities.
• Cooper's extensive experience in management and finance could benefit the company.
• The press release states that the appointment should inspire confidence going forward.
• The Co-CEO structure will allow for parallel execution of R&D, regulatory and general business operations.

Risks

• The consulting agreement can be terminated with 30 days' notice, creating potential instability.
• The success of the new Co-CEO structure depends on effective collaboration between Cooper and Dr. Dritschilo.
• The company's reliance on Cooper's ability to enhance capital markets may expose it to market risks.
• The company's future expectations are subject to various important factors, including those discussed in the Risk Factors section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company aims to improve the lives of millions impacted by cancer and bring hope to patients and families around the world by maximizing the effectiveness of radiation therapy while limiting the side effects of radiation in cancer treatment.

Management Comments

• Dr. Anatoly Dritschilo stated that Christopher Cooper's business acumen, combined with the scientific expertise of the Shuttle Pharma team, should inspire confidence going forward.
• Christopher Cooper expressed enthusiasm about joining Shuttle Pharma and improving the lives of cancer patients.

Industry Context

The appointment of a business-focused Co-CEO suggests a strategic emphasis on fundraising and business development, which is common for development-stage pharmaceutical companies seeking to advance clinical trials and commercialize their products.

Comparison to Industry Standards

• The Co-CEO structure is relatively uncommon, but can be effective in companies with distinct scientific and business operations, similar to the model used by Roche with separate Pharma and Diagnostics divisions.
• The consulting fee of $20,000 per month is within the typical range for interim executive roles in small to mid-sized pharmaceutical companies, but the overall compensation package would need to be assessed in relation to industry benchmarks for similar positions.

Management Changes

Related Party Transactions

• The company entered into a consulting agreement with Number 2 Capital Corp., a Canadian entity owned by Mr. Cooper.

Stakeholder Impact

• Shareholders may view the appointment positively, expecting improved business performance and fundraising capabilities.
• Employees may experience changes in organizational structure and responsibilities.
• Customers and partners may benefit from the company's enhanced business capabilities and focus on clinical trials.

Next Steps

• Christopher Cooper will focus on enhancing the company's capital markets and business capabilities.
• Dr. Dritschilo will continue to oversee scientific and clinical trial activities, including the Phase 2 clinical trial of Ropidoxuridine.
• The company will continue to advance the Diagnostics subsidiary.

Key Dates